**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 75999

**Manuscript Type:** LETTER TO THE EDITOR

**Electroconvulsive therapy plays an irreplaceable role in treatment of major depressive disorder**

Ma ML *et al*. ECT for major depressive disorder

Mei-Lin Ma, Lian-Ping He

**Mei-Lin Ma, Lian-Ping He,** School of Medicine, Taizhou University, Taizhou 318000, Zhejiang Province, China

**Author contributions:** Ma ML contributed to the conception of the research and wrote the letter; He LP contributed to the revision of the letter; all authors approved the final manuscript for submission.

**Supported by** the Curriculum Reform Project of Taizhou University in 2021, No. xkg2021087.

**Corresponding author: Lian-Ping He, PhD, Teacher,** School of Medicine, Taizhou University, No. 1139 Shifu Avenue, Jiaojiang District, Taizhou 318000, Zhejiang Province, China. lianpinghe@tzc.edu.cn

**Received:** February 25, 2022

**Revised:** April 20, 2022

**Accepted:** May 5, 2022

**Published online:** June 6, 2022

**Abstract**

Major depressive disorder is a serious and common neuropsychiatric disorder that affects more than 350 million people worldwide. Electroconvulsive therapy is the oldest and most effective treatment available for the treatment of severe major depressive disorder. Electroconvulsive therapy modifies structural network changes in patients with major depressive disorder and schizophrenia. And it can also affect neuroinflammatory responses and may have neuroprotective effects. Electroconvulsive therapy plays an irreplaceable role in the treatment of major depressive disorder.

**Key Words:** Depression; Electroconvulsive therapy; Major depressive disorder; Somatic cell therapy

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Ma ML, He LP. Electroconvulsive therapy plays an irreplaceable role in treatment of major depressive disorder. *World J Clin Cases* 2022; 10(16): 5515-5517

**URL**: https://www.wjgnet.com/2307-8960/full/v10/i16/5515.htm

**DOI**: https://dx.doi.org/10.12998/wjcc.v10.i16.5515

**Core Tip:** Electroconvulsive therapy has been shown to be very useful for the acute treatment of major depressive, manic, and mixed states, especially those with a high degree of suicide, as well as catatonic and drug-resistant depression. It should not be seen as a second line of defense after drug therapy.

**TO THE EDITOR**

In a recent review, Xin-Ke Li *et al*[1] expounded the neuroimaging research progress of electroconvulsive therapy (ECT) for major depressive disorder. The authors concluded that the neurobiological mechanism of ECT may be to modulate the functional activity and connectivity or neural structural plasticity of specific brain regions to normal levels for therapeutic effect. We fully agree with the authors and hereby elaborate on the importance and potential of ECT for major depressive disorder.

ECT mainly achieves therapeutic effects by increasing the synthesis and uptake of norepinephrine in the body and improving the sensitivity of serotonergic neurons. The prevailing view on the mechanism of ECT is that a cascade of reactions is triggered by electrical stimulation of specific areas of the brain. Consequently, neuronal synaptic plasticity and the levels of various neurotrophic factors and synaptic cleft transmitters are altered. Therefore, ECT has a significant therapeutic effect on a variety of mental disorders[2]. A series of studies have proved that ECT is especially suitable for major depressive disorder[3], manic acute episodes, and schizophrenia, especially some acute patients, those with acute affective symptoms, and catatonic patients[3,4].

ECT has the function of regulating the neuroinflammatory response. When subjected to external stress, there is an inflammatory response that activates indole-amine 2,3-dioxygenase and degrades TRP to kynurenine (KYN), which is metabolized to kynurenic acid (KYNA) and 3-hydroxykynurenine (3-HK). Then, KYNA and 3-HK are converted to quinolinic acid[5]. 3-HK and quinolinic acid have neurotoxic effects on the central nervous system, while KYNA is neuroprotective. Major depressive disorder exacerbates the immune inflammatory response, leading to an increase in BDNF. Several studies have shown that ECT increases KYNA levels[6]. This suggests that ECT may have neuroprotective effects.

In addition, accumulating neuroimaging evidence suggests that ECT modulates medial temporal and prefrontal cortical regions in major depressive disorder. Source-based morphometry (a multivariate statistical approach for structural data analysis) revealed that the medial temporal lobenetwork (including the hippocampus and parahippocampal cortex) was significantly increased after ECT[7]. What’s more, a study shows that brain plasticity is induced by changes in gray matter volume (GMV) during treatment for schizophrenia[8]. GMV was determined using voxel-based morphometry whole-brain analysis. These studies provide a broader perspective on the mechanism of action of ECT in the treatment of depression.

In general, ECT has played a very important role in the treatment of some depressive disorders, especially major depressive disorders. In the past decade, however, the role of physical therapy in some neuropsychiatric disorders has been underestimated or partially ignored. Most practitioners only consider ECT when a patient has failed to respond to many medication therapies. Such attempts can last months or years, delaying treatment while also increasing the patient's mental instability and prolonging their suffering. And due to a series of reasons such as ideology[9] and social environment, the role of ECT has not been fully exerted. ECT should not be seen as a last resort for psychiatric treatment.

**REFERENCES**

1 **Li XK**, Qiu HT. Current progress in neuroimaging research for the treatment of major depression with electroconvulsive therapy. *World J Psychiatry* 2022; **12**: 128-139 [PMID: 35111584 DOI: 10.5498/wjp.v12.i1.128]

2 **Lisanby SH**. Electroconvulsive therapy for depression. *N Engl J Med* 2007; **357**: 1939-1945 [PMID: 17989386 DOI: 10.1056/NEJMct075234]

3 **Weiner RD**, Reti IM. Key updates in the clinical application of electroconvulsive therapy. *Int Rev Psychiatry* 2017; **29**: 54-62 [PMID: 28406327 DOI: 10.1080/09540261.2017.1309362]

4 **Consoli A**, Benmiloud M, Wachtel L, Dhossche D, Cohen D, Bonnot O. Electroconvulsive therapy in adolescents with the catatonia syndrome: efficacy and ethics. *J ECT* 2010; **26**: 259-265 [PMID: 21099377 DOI: 10.1097/YCT.0b013e3181fb3924]

5 **Schwieler L**, Samuelsson M, Frye MA, Bhat M, Schuppe-Koistinen I, Jungholm O, Johansson AG, Landén M, Sellgren CM, Erhardt S. Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients. *J Neuroinflammation* 2016; **13**: 51 [PMID: 26925576 DOI: 10.1186/s12974-016-0517-7]

6 **Yrondi A**, Sporer M, Péran P, Schmitt L, Arbus C, Sauvaget A. Electroconvulsive therapy, depression, the immune system and inflammation: A systematic review. *Brain Stimul* 2018; **11**: 29-51 [PMID: 29111078 DOI: 10.1016/j.brs.2017.10.013]

7 **Wolf RC**, Nolte HM, Hirjak D, Hofer S, Seidl U, Depping MS, Stieltjes B, Maier-Hein K, Sambataro F, Thomann PA. Structural network changes in patients with major depression and schizophrenia treated with electroconvulsive therapy. *Eur Neuropsychopharmacol* 2016; **26**: 1465-1474 [PMID: 27424799 DOI: 10.1016/j.euroneuro.2016.06.008]

8 **Wang J**, Tang Y, Curtin A, Xia M, Tang X, Zhao Y, Li Y, Qian Z, Sheng J, Zhang T, Jia Y, Li C, Wang J. ECT-induced brain plasticity correlates with positive symptom improvement in schizophrenia by voxel-based morphometry analysis of grey matter. *Brain Stimul* 2019; **12**: 319-328 [PMID: 30473477 DOI: 10.1016/j.brs.2018.11.006]

9 **Buccelli C**, Di Lorenzo P, Paternoster M, DʼUrso G, Graziano V, Niola M. Electroconvulsive Therapy in Italy: Will Public Controversies Ever Stop? *J ECT* 2016; **32**: 207-211 [PMID: 26841302 DOI: 10.1097/YCT.0000000000000301]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no potential conﬂicts of interest with respect to the research, authorship, or publication of this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 25, 2022

**First decision:** April 18, 2022

**Article in press:** May 5, 2022

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kaur M, United States; Stoyanov D, Bulgaria **S-Editor:** Wang LL **L-Editor:** Wang TQ **P-Editor:** Wang LL



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**